Physician profile
Farha S Khan
NPI 1730121765
$348,529.04
in general payments reported to CMS, 2019-2025
30 companies · $79K in 2025
The $79K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $23K · 2021: $35K · 2022: $25K · 2023: $57K · 2024: $65K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $40K · Travel and Lodging: $27K · Consulting Fee: $6,000 · Food and Beverage: $4,863 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122,463.37 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $40,449.00 |
| Travel and Lodging | $27,028.48 |
| Consulting Fee | $6,000.00 |
| Food and Beverage | $4,863.12 |
| Education | $290.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $140,691.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $81,886.68 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $44,624.24 | 2019-2022 | |
| Dexcom, INC. | $34,643.66 | 2020-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Abbott Laboratories | $27,656.52 | 2019-2025 | Freestyle Libre 3 |
| Insulet Corporation | $16,473.74 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $1,400.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $297.06 | 2019 | |
| Ascensia Diabetes Care US INC. | $88.13 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.20 | 2021-2025 | |
| Beta Bionics, INC. | $82.33 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sanofi-Aventis U.S. LLC | $68.90 | 2020-2024 | |
| Medtronic, INC. | $57.22 | 2021-2025 | Minimed 780g |
| Radius Health, INC. | $51.70 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $46.25 | 2021-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $44.96 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $41.83 | 2021-2023 | Isturisa, Signifor Lar |
| Tandem Diabetes Care, INC. | $38.03 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $36.54 | 2021-2024 | Strensiq |
| Companion Medical, INC. | $24.30 | 2019 | |
| Valeritas, INC. | $24.17 | 2019 | |
| Amgen INC. | $23.91 | 2019 | |
| Kyowa Kirin, INC. | $22.25 | 2024 | Crysvita |
| Shire North American Group INC | $21.70 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.10 | 2021 | |
| Ionis Pharmaceuticals, INC. | $17.95 | 2025 | Tryngolza |
| Sequel Med Tech, LLC | $17.11 | 2025 | Twiist |
| Rhythm Pharmaceuticals, INC. | $16.76 | 2025 | Imcivree |
| Xeris Pharmaceuticals, INC. | $13.87 | 2025 | Recorlev |
| Cequr Corporation | $12.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farha Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.